Casma Therapeutics Announces new Nature Publication – “Structure of the lysosomal mTORC1–TFEB–Rag–Ragulator megacomplex”

January 30, 2023

In their recent Nature paper, Casma Founders Jim Hurley and Andrea Ballabio describe the cryogenic-EM structure of an MTORC1 megacomplex. A molecular description of this massive complex is helping us understand the regulation of the TFEB transcription factor and dependence of TFEB phosphorylation on FLCN and the RagC GDP state.

Read full publication here

Back to news & media

Keep reading:

News March 10, 2026
Casma Therapeutics Receives MJFF Support to Advance Research on TRPML1 in Parkinson’s Disease

Funding supports IND-enabling activities for Casma’s CSM-101, a first-in-class TRPML1 agonist targeting lysosomal dysfunction in genetically driven neurodegenerative diseases CAMBRIDGE, Mass., March 10, 2026 — Casma Therapeutics, Inc., a biotechnology company engaging the autophagy and lysosomal systems to develop innovative new medicines, today announced that it has been awarded approximately $7.6 million in funding across […]
News June 5, 2025
Casma Therapeutics Nominates CSM-101 as a Development Candidate for the Treatment of Rare and Common Forms of Parkinson’s Disease

Casma’s first-in-class TRPML1 agonist represents a new therapeutic approach for targeting lysosomal dysfunction in genetically driven neurodegenerative diseases CAMBRIDGE, Mass., June 5, 2025 — Casma Therapeutics, Inc., a biotechnology company engaging the autophagy and lysosomal systems to develop innovative new medicines, today announced the nomination of its first development candidate, CSM-101, a first-in-class TRPML1 agonist. […]